Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review
BackgroundDespite existing treatments of generalized myasthenia gravis (gMG), there remains a need for more effective therapies with fewer side effects. Telitacicept, targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), emerges as a potential novel therapy for gMG.Ca...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Neurology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fneur.2025.1501500/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576575988563968 |
|---|---|
| author | Xiaodong Song Xiaodong Song Yang He Hong Jiang Yao Yu Yue Sun Zhaoxu Zhang |
| author_facet | Xiaodong Song Xiaodong Song Yang He Hong Jiang Yao Yu Yue Sun Zhaoxu Zhang |
| author_sort | Xiaodong Song |
| collection | DOAJ |
| description | BackgroundDespite existing treatments of generalized myasthenia gravis (gMG), there remains a need for more effective therapies with fewer side effects. Telitacicept, targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), emerges as a potential novel therapy for gMG.Case presentationIn our study, four patients with gMG to standard treatments underwent an 8-week course of telitacicept monotherapy. Post-treatment, all patients exhibited satisfactory improvements. The Myasthenia Gravis Foundation of America Quantitative Myasthenia Gravis (MGFA-QMG) scores, 15-item Myasthenia Gravis Quality of Life (MGQOL-15) scores, and MG-associated Activities of Daily Living (MG-ADL) scores showed a marked reduction, indicating decreased disease severity and enhanced quality of life. Additionally, immunological assessments revealed a decrease in CD19+B lymphocyte counts and acetylcholine receptor (AChR) antibodies. Only one patient reported a mild, transient injection reaction.ConclusionFavorable clinical improvement and mild adverse events for gMG in treated with telitacicept were observed. However, larger-scale and longer-term studies are necessary to confirm these results and fully establish the role of telitacicept in the treatment of gMG. |
| format | Article |
| id | doaj-art-c94b801a55ee4239be78b6a0877e7756 |
| institution | Kabale University |
| issn | 1664-2295 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Neurology |
| spelling | doaj-art-c94b801a55ee4239be78b6a0877e77562025-01-31T05:10:24ZengFrontiers Media S.A.Frontiers in Neurology1664-22952025-01-011610.3389/fneur.2025.15015001501500Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature reviewXiaodong Song0Xiaodong Song1Yang He2Hong Jiang3Yao Yu4Yue Sun5Zhaoxu Zhang6Department of Neurology, Peking University People’s Hospital, Beijing, ChinaDepartment of Neurology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, ChinaDepartment of Neurology, Peking University People’s Hospital, Beijing, ChinaDepartment of Neurology, Peking University People’s Hospital, Beijing, ChinaDepartment of Neurology, Peking University People’s Hospital, Beijing, ChinaDepartment of Neurology, Peking University People’s Hospital, Beijing, ChinaDepartment of Neurology, Peking University People’s Hospital, Beijing, ChinaBackgroundDespite existing treatments of generalized myasthenia gravis (gMG), there remains a need for more effective therapies with fewer side effects. Telitacicept, targeting B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), emerges as a potential novel therapy for gMG.Case presentationIn our study, four patients with gMG to standard treatments underwent an 8-week course of telitacicept monotherapy. Post-treatment, all patients exhibited satisfactory improvements. The Myasthenia Gravis Foundation of America Quantitative Myasthenia Gravis (MGFA-QMG) scores, 15-item Myasthenia Gravis Quality of Life (MGQOL-15) scores, and MG-associated Activities of Daily Living (MG-ADL) scores showed a marked reduction, indicating decreased disease severity and enhanced quality of life. Additionally, immunological assessments revealed a decrease in CD19+B lymphocyte counts and acetylcholine receptor (AChR) antibodies. Only one patient reported a mild, transient injection reaction.ConclusionFavorable clinical improvement and mild adverse events for gMG in treated with telitacicept were observed. However, larger-scale and longer-term studies are necessary to confirm these results and fully establish the role of telitacicept in the treatment of gMG.https://www.frontiersin.org/articles/10.3389/fneur.2025.1501500/fullgeneralized myasthenia gravistelitaciceptB lymphocyte stimulatora proliferation-inducing ligandtreatment |
| spellingShingle | Xiaodong Song Xiaodong Song Yang He Hong Jiang Yao Yu Yue Sun Zhaoxu Zhang Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review Frontiers in Neurology generalized myasthenia gravis telitacicept B lymphocyte stimulator a proliferation-inducing ligand treatment |
| title | Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review |
| title_full | Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review |
| title_fullStr | Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review |
| title_full_unstemmed | Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review |
| title_short | Successful treatment of generalized myasthenia gravis with telitacicept: a Chinese case series and literature review |
| title_sort | successful treatment of generalized myasthenia gravis with telitacicept a chinese case series and literature review |
| topic | generalized myasthenia gravis telitacicept B lymphocyte stimulator a proliferation-inducing ligand treatment |
| url | https://www.frontiersin.org/articles/10.3389/fneur.2025.1501500/full |
| work_keys_str_mv | AT xiaodongsong successfultreatmentofgeneralizedmyastheniagraviswithtelitaciceptachinesecaseseriesandliteraturereview AT xiaodongsong successfultreatmentofgeneralizedmyastheniagraviswithtelitaciceptachinesecaseseriesandliteraturereview AT yanghe successfultreatmentofgeneralizedmyastheniagraviswithtelitaciceptachinesecaseseriesandliteraturereview AT hongjiang successfultreatmentofgeneralizedmyastheniagraviswithtelitaciceptachinesecaseseriesandliteraturereview AT yaoyu successfultreatmentofgeneralizedmyastheniagraviswithtelitaciceptachinesecaseseriesandliteraturereview AT yuesun successfultreatmentofgeneralizedmyastheniagraviswithtelitaciceptachinesecaseseriesandliteraturereview AT zhaoxuzhang successfultreatmentofgeneralizedmyastheniagraviswithtelitaciceptachinesecaseseriesandliteraturereview |